• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Menopausal Hormonal Therapy and Dementia Risk

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • A link has been suggested between menopausal hormone therapy and increased risk of developing dementia, but evidence is lacking
  • Vingradova et al. (BMJ, 2021) assessed the risks of developing dementia associated with different types and durations of menopausal hormone therapy

METHODS:

  • Nested case-control study
    • Based on 2 large UK primary care databases
      • QResearch and CPRD GOLD
  • Population
    • Cases: Women ≥55 with a primary diagnosis of dementia between 1998 and 2020
    • Controls: Matched by age, general practice, index date
  • Exposures
    • Menopausal hormone therapy
  • Study design
    • The association between dementia diagnoses and menopausal hormone treatments were quantified using odds ratios (OR)
    • Results adjusted for demographics, smoking status, alcohol consumption, comorbidities, family history, and other prescribed drugs
    • Dementia diagnoses derived from general practice, mortality, and hospital records 

RESULTS:

  • Dementia diagnoses: 118,501 women | Controls: 497,416 women
  • No difference was seen based on use of menopausal hormone therapy more than three years before the index date
    • In women with dementia: 14%
    • In controls: 14%
  • There was a decreased risk of dementia among cases and controls <80 years who had been taking estrogen-only therapy for ≥10 years
    • Adjusted OR (aOR) 0.85 (95% CI, 0.76 to 0.94)
  • Increased risks of developing specifically Alzheimer’s disease were found among women who had used estrogen-progestogen therapy for
    • Between five and nine years
      • aOR 1.11 (95% CI, 1.04 to 1.20)
      • 5 extra cases per 10,000-woman years
    • ≥10 years
      • aOR 1.19 (95% CI, 1.06 to 1.33)
      • 7 extra cases per 10,000-woman years

CONCLUSION:

  • Overall, there were no increased risks of developing dementia associated with menopausal hormone therapy  
  • There was a slightly increased risk of developing Alzheimer’s associated with long-term use of estrogen-progestogen therapy
  • The authors state

These associations do not prove any causal link, but risks of breast cancer are also associated with longer term hormone therapy use, so the results are in line with existing concerns in guidelines about long term exposures to combined hormone therapy treatments 

Learn More – Primary Sources:

Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases

BMJ Opinion: Menopausal hormone therapy and dementia

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Lancet Commission: Over a Third of Dementia Cases May be Preventable
What is the Relationship Between Antihypertensive Medications and Risk of Dementia?
Does a Healthy Lifestyle Decrease Risk of Dementia Even in Those with High Genetic Risk?

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site